A New CAR-T Cell Therapy

The FDA has recently approved a new treatment indication for CAR-T cell therapy, Yescarta (axicabtagene ciloleucel).

The treatment is now approved for patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in participating in a clinical trial, our team will gladly assist you in finding trials that are suitable for your medical needs. You are invited to respond here or contact us in a new post in this group.

For more info:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma


This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service, or treatment.


Belong.Life is a leading global tech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.

Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS), as well as i-Belong, BelongIBD, BelongPSOCoronApp (in selected countries), and more.

Belong.Life’s mission is to improve quality of life and quality of care worldwide through technology, engagement, data, and AI.

Skip to content